Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Holdings Raised by Vanguard Group Inc.

Vanguard Group Inc. increased its holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 3.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,779,561 shares of the company's stock after acquiring an additional 83,238 shares during the quarter. Vanguard Group Inc. owned approximately 4.07% of Phathom Pharmaceuticals worth $22,570,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Simplify Asset Management Inc. grew its position in shares of Phathom Pharmaceuticals by 11.5% during the fourth quarter. Simplify Asset Management Inc. now owns 581,935 shares of the company's stock worth $4,725,000 after buying an additional 60,000 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Phathom Pharmaceuticals during the 4th quarter worth $74,000. Virtu Financial LLC bought a new stake in shares of Phathom Pharmaceuticals in the 4th quarter worth about $109,000. Teacher Retirement System of Texas acquired a new stake in shares of Phathom Pharmaceuticals in the 4th quarter valued at about $90,000. Finally, Commonwealth Equity Services LLC lifted its position in shares of Phathom Pharmaceuticals by 387.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 50,772 shares of the company's stock worth $412,000 after purchasing an additional 40,362 shares during the last quarter. 99.01% of the stock is currently owned by hedge funds and other institutional investors.

Phathom Pharmaceuticals Trading Down 4.5 %

PHAT traded down $0.19 during trading on Friday, reaching $4.03. 956,148 shares of the company were exchanged, compared to its average volume of 1,011,218. The stock has a market cap of $280.64 million, a P/E ratio of -0.71 and a beta of 0.35. Phathom Pharmaceuticals, Inc. has a 52 week low of $3.81 and a 52 week high of $19.71. The firm has a 50 day moving average of $5.33 and a 200 day moving average of $8.76.

Insider Buying and Selling at Phathom Pharmaceuticals

In other Phathom Pharmaceuticals news, CFO Molly Henderson sold 6,583 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total value of $43,381.97. Following the completion of the sale, the chief financial officer now directly owns 93,546 shares in the company, valued at $616,468.14. This represents a 6.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Terrie Curran sold 19,109 shares of Phathom Pharmaceuticals stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total value of $125,928.31. Following the transaction, the insider now owns 360,465 shares in the company, valued at approximately $2,375,464.35. This trade represents a 5.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 37,256 shares of company stock valued at $238,014 in the last quarter. Corporate insiders own 24.10% of the company's stock.

Analysts Set New Price Targets

Several analysts recently weighed in on PHAT shares. The Goldman Sachs Group lowered their price objective on Phathom Pharmaceuticals from $12.00 to $10.00 and set a "neutral" rating for the company in a report on Thursday. Needham & Company LLC reissued a "buy" rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a research report on Wednesday, April 9th. Guggenheim restated a "buy" rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, April 2nd. Cantor Fitzgerald upgraded shares of Phathom Pharmaceuticals to a "strong-buy" rating in a research note on Tuesday, February 25th. Finally, Craig Hallum reissued a "buy" rating on shares of Phathom Pharmaceuticals in a report on Friday, March 7th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $21.83.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.